Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 82 articles:
HTML format
Text format



Single Articles


    December 2018
  1. WONG JYY, Downward GS, Hu W, Portengen L, et al
    Lung Cancer Risk by Geologic Coal Deposits: A Case-Control Study of Female Never-smokers from Xuanwei and Fuyuan, China.
    Int J Cancer. 2018 Dec 3. doi: 10.1002/ijc.32034.
    PubMed     Text format     Abstract available


    November 2018
  2. FANIDI A, Carreras-Torres R, Larose TL, Yuan JM, et al
    Is high vitamin B12 status a cause of lung cancer?
    Int J Cancer. 2018 Nov 29. doi: 10.1002/ijc.32033.
    PubMed     Text format     Abstract available


  3. LIN YT, Chen JS, Liao WY, Ho CC, et al
    Clinical Outcomes and Secondary Epidermal Growth Factor Receptor (EGFR) T790M Mutation among First-line Gefitinib, Erlotinib and Afatinib-treated Non-small Cell Lung Cancer Patients with Activating EGFR Mutations.
    Int J Cancer. 2018 Nov 28. doi: 10.1002/ijc.32025.
    PubMed     Text format     Abstract available


  4. WANG S, Yan B, Zhang Y, Xu J, et al
    Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation.
    Int J Cancer. 2018 Nov 25. doi: 10.1002/ijc.32015.
    PubMed     Text format     Abstract available


  5. ZHAO S, Zhang Z, Zhang Y, Hong S, et al
    Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.
    Int J Cancer. 2018 Nov 14. doi: 10.1002/ijc.31995.
    PubMed     Text format     Abstract available


  6. FORTUNATO O, Borzi C, Milione M, Centonze G, et al
    Circulating mir-320a promotes immunosuppressive macrophages M2 phenotype associated with lung cancer risk.
    Int J Cancer. 2018 Nov 13. doi: 10.1002/ijc.31988.
    PubMed     Text format     Abstract available


  7. CAI MC, Chen M, Ma P, Wu J, et al
    Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer.
    Int J Cancer. 2018 Nov 8. doi: 10.1002/ijc.31975.
    PubMed     Text format     Abstract available


    October 2018
  8. XIA Y, Cai XY, Fan JQ, Zhang LL, et al
    The role of sema4D in vasculogenic mimicry formation in non-small cell lung cancer and the underlying mechanisms.
    Int J Cancer. 2018 Oct 29. doi: 10.1002/ijc.31958.
    PubMed     Text format     Abstract available


  9. YANG YG, Koh YW, Sari IN, Jun N, et al
    Interferon-induced transmembrane protein 1-mediated EGFR/SOX2 signaling axis is essential for progression of non-small cell lung cancer.
    Int J Cancer. 2018 Oct 14. doi: 10.1002/ijc.31926.
    PubMed     Text format     Abstract available


  10. MATSUO N, Azuma K, Hattori S, Ohtake J, et al
    Association between soluble immune mediators and tumor responses in patients with non-small cell lung cancer treated with anti-PD-1 inhibitor.
    Int J Cancer. 2018 Oct 11. doi: 10.1002/ijc.31923.
    PubMed     Text format     Abstract available


    September 2018
  11. QIAN D, Liu H, Wang X, Ge J, et al
    Potentially functional genetic variants in the complement-related immunity gene-set are associated with non-small cell lung cancer survival.
    Int J Cancer. 2018 Sep 27. doi: 10.1002/ijc.31896.
    PubMed     Text format     Abstract available


  12. TREUE D, Bockmayr M, Stenzinger A, Heim D, et al
    Proteogenomic systems analysis identifies targeted therapy resistance mechanisms in EGFR-mutated lung cancer.
    Int J Cancer. 2018 Sep 5. doi: 10.1002/ijc.31845.
    PubMed     Text format     Abstract available


    August 2018
  13. LEHMAN JM, Hoeksema MD, Staub J, Qian J, et al
    Somatostatin Receptor 2 signaling promotes growth and tumor survival in Small Cell Lung Cancer.
    Int J Cancer. 2018 Aug 28. doi: 10.1002/ijc.31771.
    PubMed     Text format     Abstract available


  14. JIANG Y, Dai H, Li Y, Yin J, et al
    PARP Inhibitors Synergize with Gemcitabine by Potentiating DNA Damage in Non-Small Cell Lung Cancer.
    Int J Cancer. 2018 Aug 28. doi: 10.1002/ijc.31770.
    PubMed     Text format     Abstract available


    July 2018
  15. YUAN Q, Chen X, Han Y, Lei T, et al
    Modification of alpha2,6-sialylation mediates the invasiveness and tumorigenicity of non-small cell lung cancer cells in vitro and in vivo via Notch1/Hes1/MMPs pathway.
    Int J Cancer. 2018 Jul 7. doi: 10.1002/ijc.31737.
    PubMed     Text format     Abstract available


  16. XU Y, Liu H, Liu S, Wang Y, et al
    Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31660.
    PubMed     Text format     Abstract available


    June 2018
  17. LEE YM, Kim SJ, Lee JH, Ha E, et al
    Inhaled corticosteroids in COPD and the risk of lung cancer.
    Int J Cancer. 2018 Jun 26. doi: 10.1002/ijc.31632.
    PubMed     Text format     Abstract available


  18. LUU HN, Cai H, Murff HJ, Xiang YB, et al
    A Prospective Study of Dietary Polyunsaturated Fatty Acids Intake and Lung Cancer Risk.
    Int J Cancer. 2018 Jun 15. doi: 10.1002/ijc.31608.
    PubMed     Text format     Abstract available


    May 2018
  19. TZENG HT, Su CC, Chang CP, Lai WW, et al
    Rab37 in lung cancer mediates exocytosis of soluble ST2 and thus skews macrophages towards tumor-suppressing phenotype.
    Int J Cancer. 2018 May 1. doi: 10.1002/ijc.31569.
    PubMed     Text format     Abstract available


    April 2018
  20. LA FLEUR L, Boura VF, Alexeyenko A, Berglund A, et al
    Expression of scavenger receptor MARCO defines a targetable tumor-associated macrophage subset in non-small cell lung cancer.
    Int J Cancer. 2018 Apr 18. doi: 10.1002/ijc.31545.
    PubMed     Text format     Abstract available


    March 2018
  21. HYNDS RE, Ben Aissa A, Gowers KHC, Watkins TBK, et al
    Expansion of airway basal epithelial cells from primary human non-small cell lung cancer tumors.
    Int J Cancer. 2018 Mar 22. doi: 10.1002/ijc.31383.
    PubMed     Text format     Abstract available


  22. BOYAR CETINKAYA R, Aagnes B, Myklebust TA, Thiis-Evensen E, et al
    Survival in neuroendocrine neoplasms; A report from a large Norwegian population-based study.
    Int J Cancer. 2018;142:1139-1147.
    PubMed     Text format     Abstract available


  23. PASSIGLIA F, Galvano A, Rizzo S, Incorvaia L, et al
    Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab.
    Int J Cancer. 2018;142:1277-1284.
    PubMed     Text format     Abstract available


  24. GAO Y, Yang J, Cai Y, Fu S, et al
    IFN-gamma-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling.
    Int J Cancer. 2018 Mar 8. doi: 10.1002/ijc.31357.
    PubMed     Text format     Abstract available


  25. WANG Y, Wang C, Zhang J, Zhu M, et al
    Interaction analysis between germline susceptibility loci and somatic alterations in lung cancer.
    Int J Cancer. 2018 Mar 1. doi: 10.1002/ijc.31351.
    PubMed     Text format     Abstract available


    February 2018
  26. WEI Y, Zhou F, Zhou H, Huang J, et al
    Endothelial progenitor cells contribute to neovascularization of non-small cell lung cancer via HDAC7 mediated cytoskeleton regulation and angiogenic genes transcription.
    Int J Cancer. 2018 Feb 28. doi: 10.1002/ijc.31349.
    PubMed     Text format     Abstract available


  27. CHO J, Kim S, Du J, Meyerson M, et al
    Autophosphorylation of the C-terminal domain is not required for oncogenic transformation by lung-cancer derived EGFR mutants.
    Int J Cancer. 2018 Feb 21. doi: 10.1002/ijc.31332.
    PubMed     Text format     Abstract available


  28. LI X, Wang Y, Wang J, Zhang T, et al
    Enhanced efficacy of AZD3759 and radiation on brain metastasis from EGFR mutant non-small cell lung cancer.
    Int J Cancer. 2018 Feb 12. doi: 10.1002/ijc.31303.
    PubMed     Text format     Abstract available


  29. JIANG Z, Chen T, Chen J, Ying S, et al
    Hand-spinning chrysotile exposure and risk of malignant mesothelioma: A case-control study in Southeastern China.
    Int J Cancer. 2018;142:514-523.
    PubMed     Text format     Abstract available


    January 2018
  30. NARITA S, Saito E, Sawada N, Shimazu T, et al
    Dietary Consumption of Antioxidant Vitamins and Subsequent Lung Cancer Risk: The Japan Public Health Center-based Prospective Study.
    Int J Cancer. 2018 Jan 22. doi: 10.1002/ijc.31268.
    PubMed     Text format     Abstract available


  31. SETTE G, Salvati V, Giordani I, Pillozzi E, et al
    Conditionally reprogrammed cells (CRC) methodology does not allow the in vitro expansion of patient-derived primary and metastatic lung cancer cells.
    Int J Cancer. 2018 Jan 17. doi: 10.1002/ijc.31260.
    PubMed     Text format     Abstract available


  32. INOUE-CHOI M, Hartge P, Liao LM, Caporaso N, et al
    Association between long-term low-intensity cigarette smoking and incidence of smoking-related cancer in the national institutes of health-AARP cohort.
    Int J Cancer. 2018;142:271-280.
    PubMed     Text format     Abstract available


  33. XU X, Huang Z, Zheng L, Fan Y, et al
    The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer.
    Int J Cancer. 2018 Jan 10. doi: 10.1002/ijc.31252.
    PubMed     Text format     Abstract available


  34. MORRIS S, Vachani A, Pass HI, Rom WN, et al
    Whole Blood FPR1 mRNA Expression Predicts Both Non-Small Cell and Small Cell Lung Cancer.
    Int J Cancer. 2018 Jan 5. doi: 10.1002/ijc.31245.
    PubMed     Text format     Abstract available


  35. YANG TY, Teng CJ, Lin TC, Chen KC, et al
    Transcriptional repression of Aurora-A gene by wild-type p53 through directly binding to its promoter with histone deacetylase 1 and mSin3a.
    Int J Cancer. 2018;142:92-108.
    PubMed     Text format     Abstract available


    December 2017
  36. DAI L, Smith CD, Foroozesh M, Miele L, et al
    The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo.
    Int J Cancer. 2017 Dec 26. doi: 10.1002/ijc.31234.
    PubMed     Text format     Abstract available


  37. WU Y, Shi H, Jiang M, Qiu M, et al
    The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety.
    Int J Cancer. 2017;141:2562-2570.
    PubMed     Text format     Abstract available


  38. THEOFYLAKTOPOULOU D, Midttun O, Ueland PM, Meyer K, et al
    Impaired functional vitamin B6 status is associated with increased risk of lung cancer.
    Int J Cancer. 2017 Dec 14. doi: 10.1002/ijc.31215.
    PubMed     Text format     Abstract available


  39. ZHENG Y, Deng Z, Yin J, Wang S, et al
    The association of genetic variations in DNA repair pathways with severe toxicities in NSCLC patients undergoing platinum-based chemotherapy.
    Int J Cancer. 2017;141:2336-2347.
    PubMed     Text format     Abstract available


  40. DETTERBECK FC
    Letter to the Editor: Re: The Impact of Overdiagnosis on the Selection of Efficient Lung Cancer Screening Strategies.
    Int J Cancer. 2017 Dec 1. doi: 10.1002/ijc.31185.
    PubMed     Text format    


    November 2017
  41. WANG Y, Wu W, Zhu M, Wang C, et al
    Integrating expression related SNPs into genome-wide gene-pathway-based analysis identified novel lung cancer susceptibility genes.
    Int J Cancer. 2017 Nov 30. doi: 10.1002/ijc.31182.
    PubMed     Text format     Abstract available


  42. ZHAO S, Gao F, Zhang Y, Zhang Z, et al
    Bevacizumab in Combination with Different Platinum-based Doublets in the First-line Treatment for Advanced Nonsquamous Non-small-cell Lung Cancer: A Network Meta-Analysis.
    Int J Cancer. 2017 Nov 24. doi: 10.1002/ijc.31175.
    PubMed     Text format     Abstract available


  43. LI Y, Ye Z, Chen S, Pan Z, et al
    ARHGEF19 interacts with BRAF to activate MAPK signaling during the tumorigenesis of non-small cell lung cancer.
    Int J Cancer. 2017 Nov 22. doi: 10.1002/ijc.31169.
    PubMed     Text format     Abstract available


  44. SATTERFIELD L, Shuck R, Kurenbekova L, Allen-Rhoades W, et al
    miR-130b directly targets ARHGAP1 to drive activation of a metastatic CDC42-PAK1-AP1 positive feedback loop in Ewing sarcoma.
    Int J Cancer. 2017;141:2062-2075.
    PubMed     Text format     Abstract available


  45. KIM J, Field A, Schultz KAP, Hill DA, et al
    The prevalence of DICER1 pathogenic variation in population databases.
    Int J Cancer. 2017;141:2030-2036.
    PubMed     Text format     Abstract available


  46. UNVER N, Delgado O, Zeleke K, Cumpian A, et al
    Reduced IL-6 levels and tumor-associated phospho-STAT3 are associated with reduced tumor development in a mouse model of lung cancer chemoprevention with myo-inositol.
    Int J Cancer. 2017 Nov 14. doi: 10.1002/ijc.31152.
    PubMed     Text format     Abstract available


  47. ZHANG R, Jia M, Xu Y, Qian D, et al
    ERCC4 regulatory variant predict Grade-3 or -4 toxicities in patients with advanced non-small cell lung cancer treated by platinum-based therapy.
    Int J Cancer. 2017 Nov 14. doi: 10.1002/ijc.31153.
    PubMed     Text format     Abstract available


  48. DIETZ S, Harms A, Endris V, Eichhorn F, et al
    Spatial distribution of EGFR and KRAS mutation frequencies correlates with histological growth patterns of lung adenocarcinomas.
    Int J Cancer. 2017;141:1841-1848.
    PubMed     Text format     Abstract available


    October 2017
  49. FUJIMOTO J, Nunomura-Nakamura S, Liu Y, Lang W, et al
    Development of Kras mutant lung adenocarcinoma in mice with knockout of the airway lineage-specific gene Gprc5a.
    Int J Cancer. 2017;141:1589-1599.
    PubMed     Text format     Abstract available


  50. LIU HX, Tao LL, Zhang J, Zhu YG, et al
    Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects.
    Int J Cancer. 2017 Oct 11. doi: 10.1002/ijc.31098.
    PubMed     Text format     Abstract available


    September 2017
  51. BRYANT JL, Gieling RG, Meredith SL, Allen TJ, et al
    Novel carbonic anhydrase IX-targeted therapy enhances the anti-tumour effects of cisplatin in small cell lung cancer.
    Int J Cancer. 2017 Sep 14. doi: 10.1002/ijc.31042.
    PubMed     Text format     Abstract available


    August 2017
  52. ZHANG K, Wang J, Tong TR, Wu X, et al
    Loss of H2B monoubiquitination is associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma.
    Int J Cancer. 2017;141:766-777.
    PubMed     Text format     Abstract available


  53. GUPTA SK, Guzman EAT, Meenach SA
    Co-administration of a tumor-penetrating peptide improves the therapeutic efficacy of paclitaxel in a novel air-grown lung cancer 3D spheroid model.
    Int J Cancer. 2017 Aug 2. doi: 10.1002/ijc.30913.
    PubMed     Text format     Abstract available


    July 2017
  54. LI W, Xie SH, Tse LA, Lagergren J, et al
    Digitalis Use and Lung Cancer Risk by Histological Type in Men.
    Int J Cancer. 2017 Jul 27. doi: 10.1002/ijc.30908.
    PubMed     Text format     Abstract available


  55. MORAVCIKOVA E, Krepela E, Donnenberg VS, Donnenberg AD, et al
    BOK displays cell death-independent tumor suppressor activity in non-small cell lung carcinoma.
    Int J Cancer. 2017 Jul 26. doi: 10.1002/ijc.30906.
    PubMed     Text format     Abstract available


  56. KETTUNEN E, Hernandez-Vargas H, Cros MP, Durand G, et al
    Asbestos-associated genome-wide DNA methylation changes in lung cancer.
    Int J Cancer. 2017 Jul 19. doi: 10.1002/ijc.30897.
    PubMed     Text format     Abstract available


  57. LEE WY, Chen PC, Wu WS, Wu HC, et al
    Panobinostat Sensitizes KRAS-Mutant Non-Small Cell Lung Cancer to Gefitinib by Targeting TAZ.
    Int J Cancer. 2017 Jul 14. doi: 10.1002/ijc.30888.
    PubMed     Text format     Abstract available


  58. GU F, Zhang H, Hyland PL, Berndt S, et al
    Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia.
    Int J Cancer. 2017 Jul 12. doi: 10.1002/ijc.30883.
    PubMed     Text format     Abstract available


  59. KNIPS J, Czech-Sioli M, Spohn M, Heiland M, et al
    Spontaneous lung metastasis formation of human Merkel cell carcinoma cell lines transplanted into scid mice.
    Int J Cancer. 2017;141:160-171.
    PubMed     Text format     Abstract available


    May 2017
  60. XIE K, Chen M, Zhu M, Wang C, et al
    A polymorphism in miR-1262 regulatory region confers the risk of lung cancer in Chinese population.
    Int J Cancer. 2017 May 16. doi: 10.1002/ijc.30788.
    PubMed     Text format     Abstract available


  61. NAJMEH S, Cools-Lartigue J, Rayes RF, Gowing S, et al
    Neutrophil extracellular traps sequester circulating tumor cells via beta1-integrin mediated interactions.
    Int J Cancer. 2017;140:2321-2330.
    PubMed     Text format     Abstract available


  62. MEYERS TJ, Chang SC, Chang PY, Morgenstern H, et al
    Case-control study of cumulative cigarette tar exposure and lung and upper aerodigestive tract cancers.
    Int J Cancer. 2017;140:2040-2050.
    PubMed     Text format     Abstract available


    April 2017
  63. LOBB RJ, van Amerongen R, Wiegmans A, Ham S, et al
    Exosomes derived from mesenchymal non-small cell lung cancer cells promote chemoresistance.
    Int J Cancer. 2017 Apr 26. doi: 10.1002/ijc.30752.
    PubMed     Text format     Abstract available


  64. BEN KHEDHER S, Neri M, Papadopoulos A, Christiani DC, et al
    Menstrual and reproductive factors and lung cancer risk: A pooled analysis from the International Lung Cancer consortium (ILCCO).
    Int J Cancer. 2017 Apr 25. doi: 10.1002/ijc.30750.
    PubMed     Text format     Abstract available


  65. WANG SS, Zimmermann M, Zhang H, Lin TY, et al
    A Diagnostic Microdosing Approach to Investigate Platinum Sensitivity in Non-Small Cell Lung Cancer.
    Int J Cancer. 2017 Apr 24. doi: 10.1002/ijc.30747.
    PubMed     Text format     Abstract available


  66. GROMOWSKI T, Gapska P, Scott RJ, Kaklewski K, et al
    Serum 25(OH)D concentration, common variants of the VDR gene and lung cancer occurrence.
    Int J Cancer. 2017 Apr 15. doi: 10.1002/ijc.30740.
    PubMed     Text format     Abstract available


  67. GOWING SD, Chow SC, Cools-Lartigue JJ, Chen CB, et al
    Gram-Positive Pneumonia Augments Non-Small Cell Lung Cancer Metastasis Via Host Toll-like Receptor 2 Activation.
    Int J Cancer. 2017 Apr 12. doi: 10.1002/ijc.30734.
    PubMed     Text format     Abstract available


  68. CAROZZI FM, Bisanzi S, Carrozzi L, Falaschi F, et al
    Multimodal lung cancer screening using the ITALUNG Biomarker Panel and Low Dose Computed Tomography. Results of the ITALUNG biomarker study.
    Int J Cancer. 2017 Apr 7. doi: 10.1002/ijc.30727.
    PubMed     Text format     Abstract available


  69. HELLAND A, Brustugun OT, Nakken S, Halvorsen AR, et al
    High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival.
    Int J Cancer. 2017 Apr 7. doi: 10.1002/ijc.30726.
    PubMed     Text format     Abstract available


  70. LIN J, Gill A, Zahm SH, Carter CA, et al
    Metformin Use and Survival after Non-Small Cell Lung Cancer: A Cohort Study in the U.S. Military Health System.
    Int J Cancer. 2017 Apr 5. doi: 10.1002/ijc.30724.
    PubMed     Text format     Abstract available


  71. FRANK C, Sundquist J, Yu H, Hemminki A, et al
    Concordant and discordant familial cancer: Familial risks, proportions and population impact.
    Int J Cancer. 2017;140:1510-1516.
    PubMed     Text format     Abstract available


  72. RAASCHOU-NIELSEN O, Pedersen M, Stafoggia M, Weinmayr G, et al
    Outdoor air pollution and risk for kidney parenchyma cancer in 14 European cohorts.
    Int J Cancer. 2017;140:1528-1537.
    PubMed     Text format     Abstract available


  73. TANG Z, Li J, Shen Q, Feng J, et al
    Contribution of upregulated dipeptidyl peptidase 9 (DPP9) in promoting tumoregenicity, metastasis and the prediction of poor prognosis in non-small cell lung cancer (NSCLC).
    Int J Cancer. 2017;140:1620-1632.
    PubMed     Text format     Abstract available


    March 2017
  74. DONG J, Cheng Y, Zhu M, Wen Y, et al
    Fine Mapping of Chromosome 5p15.33 Identifies Novel Lung Cancer Susceptibility Loci in Han Chinese.
    Int J Cancer. 2017 Mar 23. doi: 10.1002/ijc.30702.
    PubMed     Text format     Abstract available


  75. GOLDWASSER DL
    Estimation of the tumor size at cure threshold among aggressive non-small cell lung cancers (NSCLCs): evidence from the surveillance, epidemiology, and end results (SEER) program and the national lung screening trial (NLST).
    Int J Cancer. 2017;140:1280-1292.
    PubMed     Text format     Abstract available


  76. SHI H, Zhang J, Han X, Li H, et al
    Recruited monocytic myeloid-derived suppressor cells promote the arrest of tumor cells in the premetastatic niche through an IL-1beta-mediated increase in E-selectin expression.
    Int J Cancer. 2017;140:1370-1383.
    PubMed     Text format     Abstract available


    January 2017
  77. ZHANG LL, Kan M, Zhang MM, Yu SS, et al
    Multiregion sequencing reveals the intratumor heterogeneity of driver mutations in TP53-driven non-small cell lung cancer.
    Int J Cancer. 2017;140:103-108.
    PubMed     Text format     Abstract available


  78. KAMMERER-JACQUET SF, Crouzet L, Brunot A, Dagher J, et al
    Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potential.
    Int J Cancer. 2017;140:142-148.
    PubMed     Text format     Abstract available


  79. VAZQUEZ R, Licandro SA, Astorgues-Xerri L, Lettera E, et al
    Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts.
    Int J Cancer. 2017;140:197-207.
    PubMed     Text format     Abstract available


    December 2016
  80. MANDRIOTA SJ, Tenan M, Ferrari P, Sappino AP, et al
    Aluminium chloride promotes tumorigenesis and metastasis in normal murine mammary gland epithelial cells.
    Int J Cancer. 2016;139:2781-2790.
    PubMed     Text format     Abstract available


    November 2016
  81. LI L, Yang L, Wang L, Wang F, et al
    Impaired T cell function in malignant pleural effusion is caused by TGF-beta derived predominantly from macrophages.
    Int J Cancer. 2016;139:2261-9.
    PubMed     Text format     Abstract available


    October 2016
  82. TRABERT B, Eldridge RC, Pfeiffer RM, Shiels MS, et al
    Pre-diagnostic circulating inflammation markers and endometrial cancer risk in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial.
    Int J Cancer. 2016 Oct 22. doi: 10.1002/ijc.30478.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: